Ads
related to: genentech
Search results
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Benzinga via Yahoo Finance· 5 days agoThursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b...
Best Ads of the Week: Coi Leray kicks it with Foot Locker & Dove decodes mom life with AI
The Drum· 6 days agoThis week, Editora Taverna fought the good fight against gay conversion therapy Brazil, Vivo rallied...
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
Clinical Trials Arena via Yahoo Finance· 6 days agoThe Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene...
No Improvement in OS With Atezolizumab in Relapsing TNBC
Medscape· 1 day agoEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast...
Mirikizumab Shows Promise for Moderate to Severe Crohn's
Medscape· 1 day agoAlready approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for...
Biotech company lays off over a hundred Bay Area workers
San Francisco Chronicle· 4 days agoBioMarin Pharmaceutical, a San Rafael-based biotech company specializing in drugs for genetic...
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with...
Morningstar· 17 hours agoPRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...
Once-Promising Drug for Idiopathic Pulmonary Fibrosis Fails in Phase III Trial
MedPage Today· 1 day agoThe fully human monoclonal antibody pamrevlumab failed to improve lung function among patients with idiopathic pulmonary fibrosis (IPF) in the randomized ZEPHYRUS-1 trial, despite showing positive ...
Spyre Therapeutics names Sandra Milligan to board By Investing.com
Investing.com· 6 days agoSpyre Therapeutics, Inc. (NASDAQ: SYRE), a biotechnology company focusing on the development of...
Perioperative Nivolumab Boosts EFS in Resectable Lung Cancer
MedPage Today· 6 days agoCheckMate 77T trial shows 42% reduction in risk of tumor recurrence, progression, or death
Ad
related to: genentech